Tiziana Life Sciences PLC (LON:TILS – Get Free Report) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 58.50 ($0.73) and traded as low as GBX 45 ($0.56). Tiziana Life Sciences shares last traded at GBX 58.50 ($0.73), with a volume of 297,127 shares.
Tiziana Life Sciences Price Performance
The company has a market capitalization of £113.85 million and a PE ratio of -3.59. The company has a current ratio of 6.54, a quick ratio of 6.41 and a debt-to-equity ratio of 2.36. The stock has a fifty day simple moving average of GBX 58.50 and a 200-day simple moving average of GBX 58.50.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
Featured Articles
- Five stocks we like better than Tiziana Life Sciences
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Silicon Motion Proves That AI in Motion Stays in Motion
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Undervalued UnitedHealth Group Won’t Be For Long
- What is a Low P/E Ratio and What Does it Tell Investors?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.